Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 24, 2025
A Study of Ramelteon in Chinese Patients With Chronic Insomnia
Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Ramelteon
Therapeutic Area : Sleep
Study Phase : Phase IV
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Insomnia Prevalence and Treatment Impact on Systemic Hypertension
Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Ramelteon
Therapeutic Area : Sleep
Highest Development Status : Phase IV
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramelteon
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Upsher-Smith Launches Ramelteon Tablets
Details : Upsher-Smith’s product is AB-rated to the branded product, ROZEREM® (ramelteon) tablets.* Ramelteon tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset.
Product Name : Rozerem
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2020
Lead Product(s) : Ramelteon
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ramelteon for Complex Insomnia in Veterans With PTSD
Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2017
Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 29, 2016
Lead Product(s) : Ramelteon
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2012
Lead Product(s) : Ramelteon
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramelteon
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 31, 2012
Lead Product(s) : Ramelteon
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramelteon
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2011
Lead Product(s) : Ramelteon
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramelteon
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2011
Lead Product(s) : Ramelteon
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
